Major depressive disorder (MDD) and bipolar disorder are among the leading causes of disability worldwide. However, their pathophysiological mechanisms ...

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...

Although antidepressants are a mainstay of MDD treatment, they are plagued by poor efficacy, high rates of relapse, and intolerable side effects. 40,41 Second-generation antidepressants, including ...

Neumora Therapeutics, Inc. (NMRA) is gearing up to report results from one of its phase 3 studies, which is using its drug Navacaprant for the treatment of patients with major depressive disorder (MDD ...

Researchers found that 8.3% of US adults had at least one major depressive episode. In adolescents, the rate was 20.1%, with 29.2% of female adolescents reporting a major depressive episode. Major ...

SOUTH SAN FRANCISCO, Calif. & MUNICH--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel ...

17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of ...

FREMONT, CA - January 15, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous ...

Rates of depression notably spiked during the pandemic. But even though life has largely returned to normal, we’re still in a mental health crisis. In 2023, the U.S. Surgeon General declared an ...